-
公开(公告)号:US20140187753A1
公开(公告)日:2014-07-03
申请号:US14167712
申请日:2014-01-29
发明人: Stanislas Blein , Darko Skegro , Paul Wassmann
IPC分类号: C07K16/46
CPC分类号: C07K16/46 , C07K16/18 , C07K16/2803 , C07K16/2842 , C07K16/2863 , C07K16/32 , C07K16/468 , C07K2317/50 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/622 , C07K2317/94 , C07K2319/00
摘要: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
摘要翻译: 本发明涉及工程化的异二聚体免疫球蛋白或其片段及其制备方法。
-
公开(公告)号:US09683053B2
公开(公告)日:2017-06-20
申请号:US14167712
申请日:2014-01-29
发明人: Stanislas Blein , Darko Skegro , Paul Wassmann
CPC分类号: C07K16/46 , C07K16/18 , C07K16/2803 , C07K16/2842 , C07K16/2863 , C07K16/32 , C07K16/468 , C07K2317/50 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/622 , C07K2317/94 , C07K2319/00
摘要: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
-
公开(公告)号:US20140294824A1
公开(公告)日:2014-10-02
申请号:US14222421
申请日:2014-03-21
IPC分类号: C07K16/28
CPC分类号: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/70578
摘要: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
摘要翻译: 本发明涉及与人OX40结合的拮抗剂抗体或其片段。 更具体地,本发明涉及与人OX40结合的拮抗剂抗体或其片段,其包含包含SEQ ID NO:1的氨基酸序列的重链CDR1和/或包含SEQ ID NO:1的氨基酸序列的重链CDR2 ID NO:2,和/或包含SEQ ID NO:3的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO:4的氨基酸序列的轻链CDR1和/或包含SEQ ID NO:5的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO:6。
-
公开(公告)号:US09493563B2
公开(公告)日:2016-11-15
申请号:US14532923
申请日:2014-11-04
发明人: Stanislas Blein , Romain Ollier , Darko Skegro , Samuel Hou
CPC分类号: C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/32 , C07K16/4291 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
-
公开(公告)号:US09290576B2
公开(公告)日:2016-03-22
申请号:US14146566
申请日:2014-01-02
IPC分类号: A61K39/395 , C07K16/28 , A61K47/48 , A61K39/00
CPC分类号: C07K16/2878 , A61K39/3955 , A61K47/6849 , A61K2039/505 , C07K16/2875 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
摘要翻译: 本发明涉及与TL1A结合的抗体或其片段。 更具体地说,本发明涉及与TL1A结合的抗体或其片段,其包含包含SEQ ID NO:51的氨基酸序列的重链CDR1和/或包含SEQ ID NO的氨基酸序列的重链CDR2 :52,和/或包含SEQ ID NO:53的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO:54的氨基酸序列的轻链CDR1和/或包含SEQ ID NO:55的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO:56。
-
公开(公告)号:US20170260280A1
公开(公告)日:2017-09-14
申请号:US15348774
申请日:2016-11-10
IPC分类号: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC分类号: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/70578
摘要: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
-
公开(公告)号:US20150239991A1
公开(公告)日:2015-08-27
申请号:US14431207
申请日:2013-09-25
发明人: Stanislas Blein , Fabrizio Comper , Romain Ollier , Paul Wassmann
IPC分类号: C07K16/46
CPC分类号: C07K16/468 , B01D15/3809 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/567 , C07K2317/622
摘要: The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.
摘要翻译: 本发明描述了具有减少或消除与蛋白A,蛋白G或蛋白A和蛋白G两者结合的新型异二聚体免疫球蛋白变体或其片段。本发明还包括用于选择性纯化异二聚体免疫球蛋白的方法 或其片段使用蛋白A和蛋白G.
-
-
-
-
-
-